On May 1, a three-judge panel of the 5th U.S. Circuit Court of Appeals in New Orleans issued a temporary injunction that prevents a federal regulation from being implemented which had permitted the abortion drug mifepristone to be dispensed through the mail.
The court said the state of Louisiana is likely to prevail in its legal challenge to the 2023 rule. That regulation, adopted by the administration of Democratic former President Joe Biden, removed a prior condition requiring that mifepristone be handed to patients in person.
Although the appeals court emphasized the temporary nature of its decision, the order represents the first time in a series of lawsuits contesting the drug's regulatory pathway that access to mifepristone has been significantly limited. The litigation tracks back to the drug's initial approval in 2000 and subsequent regulatory steps intended to broaden access.
The injunction constrains mail-order distribution of mifepristone nationwide and is likely to have immediate consequences in states where abortion has been restricted or banned. By blocking the 2023 rule, the court effectively reinstates the in-person dispensing requirement while the legal challenge proceeds.
Legal observers and healthcare stakeholders will be watching how lower courts and regulators respond to the 5th Circuit's interim order, and whether this temporary block becomes the basis for more lasting restrictions as the case advances. For now, the ruling narrows one pathway through which patients had been obtaining the medication since the 2023 change.
Because the order is an interim ruling, it does not resolve the underlying dispute over the 2023 regulation or the broader series of lawsuits concerning mifepristone's approval and subsequent regulatory modifications. Further proceedings will determine whether the court's assessment that Louisiana is likely to prevail is borne out as the litigation unfolds.
Context preserved from the ruling:
- The 5th U.S. Circuit Court of Appeals issued a temporary block on May 1.
- The state of Louisiana brought the challenge to the 2023 rule.
- The 2023 rule, adopted under Democratic former President Joe Biden’s administration, removed an in-person dispensing requirement for mifepristone.
- Mifepristone was initially approved in 2000.